Page last updated: 2024-11-06

4-nitrophenyl beta-d-glucoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Nitrophenyl beta-D-glucoside (4-NPG) is a synthetic substrate for beta-glucosidase enzymes. Its synthesis typically involves the reaction of 4-nitrophenol with beta-D-glucose in the presence of a catalyst. 4-NPG is commonly used in research as a chromogenic substrate for beta-glucosidase activity assays. Upon hydrolysis by beta-glucosidase, it releases 4-nitrophenol, which absorbs strongly in the visible region, allowing for easy spectrophotometric detection. 4-NPG has been used to study the kinetics and mechanism of beta-glucosidase enzymes, as well as to screen for inhibitors of these enzymes. It has also been investigated for its potential applications in various fields, including the production of biofuels, the development of diagnostic tools, and the synthesis of novel pharmaceuticals.'
```

4-nitrophenyl beta-D-glucoside: RN given refers to (beta)-anomer; see also (alpha)-anomer: 3767-28-0; cpd with unspecified anomer: 5779-46-4 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-nitrophenyl beta-D-glucoside : A beta-D-glucoside that is beta-D-glucopyranose in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID92930
CHEMBL ID152723
CHEBI ID90259
SCHEMBL ID78954
MeSH IDM0084276

Synonyms (50)

Synonym
para-nitrophenyl b-d-glucopyranoside
.beta.-d-glucopyranoside, 4-nitrophenyl
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-(4-nitrophenoxy)tetrahydropyran-3,4,5-triol
glucoside, p-nitrophenyl
4-nitrophenyl beta-d-glucoside
p-nitrophenyl beta-glucoside
2492-87-7
p-nitrophenyl beta-d-glucopyranoside
4-nitrophenyl beta-d-glucopyranoside
glucopyranoside, p-nitrophenyl, beta-d- (6ci,7ci,8ci)
1-o-p-nitrophenyl-d-glucose
beta-d-glucopyranoside, 4-nitrophenyl (9ci)
pnpg
beta-d-glucopyranoside, 4-nitrophenyl
p-nitrophenyl-beta-glucoside
p-nitrophenyl beta-d-glucoside
p-nitrophenol beta-d-glucoside
4-nitrophenyl beta-d-glucopyranoside, >=98% (tlc)
4-nitrophenyl-beta-d-glucopyranoside
CHEMBL152723
chebi:90259 ,
pnw ,
N0235
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-(4-nitrophenoxy)oxane-3,4,5-triol
AKOS003631966
p-nitrophenyl-beta-d-glucoside
pnpbetaglu
4-nitrophenyl-beta-d-glucoside
bdbm84613
einecs 219-661-3
AKOS016015681
AM84833
HY-15927
SCHEMBL78954
4-nitrophenyl beta-d-glucopyranoside monohydrate
mfcd00006593
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-(4-nitrophenoxy)tetrahydro-2h-pyran-3,4,5-triol
4-nitrophenyl-i(2)-d-glucopyranoside
CCG-233291
GS-6255
Q27162435
H10200
A877766
4-nitrophenyl- beta -d- glucopyranoside
pnp-beta-d-glc
DTXSID40883854
4-nitrophenyl b-d-glucopyranoside4-nitrophenyl b-d-glucopyranoside
p-nitrophenyl ?-d-glucopyranoside
wurcs=2.0/1,1,0/[a2122h-1b_1-5_1*o(c^ec^zc^ec^ec^zc^e$3)/6no/9=o]/1/
AKOS040744347

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"34 microL/min/cm, mean +/- SE, N = 4), calculated by dividing the absorption rate by the drug concentration, was significantly decreased (0."( Intestinal active absorption of sugar-conjugated compounds by glucose transport system: implication of improvement of poorly absorbable drugs.
Awazu, S; Hayashi, M; Mizuma, T; Ohta, K, 1992
)
0.28
"Active absorption in the intestine and metabolism of the beta- and alpha-anomers of the glucoside and galactoside of p-nitrophenol (p-NP) were studied to find a more suitable prodrug for poorly absorbed drugs."( Comparative study of active absorption by the intestine and disposition of anomers of sugar-conjugated compounds.
Awazu, S; Hayashi, M; Mizuma, T; Ohta, K, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
chromogenic compoundColourless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into coloured compounds. They are used in biochemical assays and in diagnosis as indicators, particularly in the form of enzyme substrates.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
beta-D-glucosideAny D-glucoside in which the anomeric centre has beta-configuration.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 16Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 16Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityTaste receptor type 2 member 16Homo sapiens (human)
protein bindingTaste receptor type 2 member 16Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 16Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
endoplasmic reticulumTaste receptor type 2 member 16Homo sapiens (human)
trans-Golgi networkTaste receptor type 2 member 16Homo sapiens (human)
plasma membraneTaste receptor type 2 member 16Homo sapiens (human)
external side of plasma membraneTaste receptor type 2 member 16Homo sapiens (human)
membraneTaste receptor type 2 member 16Homo sapiens (human)
membraneTaste receptor type 2 member 16Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID191620Specific activity of the stomach segment in rat intestine1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Drug glycosides: potential prodrugs for colon-specific drug delivery.
AID1752330Inhibition of adipogenesis in mouse C3H10T1/2 cells assessed as lipid droplet formation at 20 uM by Oil red O staining relative to control2021Bioorganic & medicinal chemistry letters, 10-15, Volume: 50Ginkgonitroside, a new nitrophenyl glycoside and bioactive compounds from Ginkgo biloba leaves controlling adipocyte and osteoblast differentiation.
AID18316Km(app) value was determined in homogenates of pooled cecal contents in rats1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Drug glycosides: potential prodrugs for colon-specific drug delivery.
AID22831Vmax value was determined in homogenates of pooled cecal contents in rats1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Drug glycosides: potential prodrugs for colon-specific drug delivery.
AID191617Specific activity of the DSI segment in rat intestine1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Drug glycosides: potential prodrugs for colon-specific drug delivery.
AID190824Total activity of the entire contents of DSI segment in rat intestine1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Drug glycosides: potential prodrugs for colon-specific drug delivery.
AID190827Total activity of the entire contents of stomach segment in rat intestine1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Drug glycosides: potential prodrugs for colon-specific drug delivery.
AID191619Specific activity of the cecum segment in rat intestine1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Drug glycosides: potential prodrugs for colon-specific drug delivery.
AID190826Total activity of the entire contents of cecum segment in rat intestine1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Drug glycosides: potential prodrugs for colon-specific drug delivery.
AID191618Specific activity of the PSI segment in rat intestine1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Drug glycosides: potential prodrugs for colon-specific drug delivery.
AID190825Total activity of the entire contents of PSI segment in rat intestine1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
Drug glycosides: potential prodrugs for colon-specific drug delivery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (73)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (20.55)18.7374
1990's21 (28.77)18.2507
2000's13 (17.81)29.6817
2010's23 (31.51)24.3611
2020's1 (1.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.28 (24.57)
Research Supply Index4.36 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other77 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]